RxDoctor Payments Data

Betty Hamilton, MD

Hematology & Oncology · Cleveland, OHNPI 1235293572

Payments from drug & device makers

$479,501in general payments, 2019–2025

Across 133 payments — averaging $3605.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$193K
  • Deciphera Pharmaceuticals Inc.$109K
  • Incyte Corporation$98K
  • National Marrow Donor Program$41K
  • Sanofi-aventis U.S. LLC$20K
  • Amgen$13K
  • plus $5K from 5 others

What the payments were for

  • Consulting fees$27,67849%
  • Speaking & faculty fees$23,66042%
  • Travel & lodging$2,7695%
  • Food & beverage$2,0964%
  • Education$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$479,501 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$36,801
Medicare patients
72
Services billed
468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezurockBelumosudil Mesylate63$1,999,350
JakafiRuxolitinib Phosphate83$1,183,094
Posaconazole29$64,396
XareltoRivaroxaban13$18,341
EliquisApixaban21$14,606
JardianceEmpagliflozin11$6,751
Budesonide DrBudesonide28$3,599
Sirolimus15$2,469
Budesonide EcBudesonide12$1,936
Acyclovir173$1,761
Tacrolimus28$1,223
Fluconazole35$1,127
Ondansetron Hcl17$1,104
Dexamethasone43$1,090
Azithromycin27$721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCRezurock$19,853$1,999,35063 claims
Incyte CorporationJakafi$98,099$1,183,09483 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →